Study of BRAF V600E mutant colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at colorectal cancer with a specific gene change called BRAF V600E. It aims to learn more about the cancer and may help guide future treatment. If you have this gene change, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has been confirmed by a biopsy or cytology.
- You are 18 years old or older.
- Your tumor has a specific gene change called BRAF V600E, shown by a prior genetic test.
- You have not received more than two prior treatments for your colorectal cancer.
- You are not pregnant or breastfeeding.
- You are willing and able to provide blood or tumor samples and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
This real-world study looks at how doctors’ standard treatment works for metastatic colorectal cancer that has a specific BRAF mutation (BRAF V600E). It focuses on patients who are already starting—or will soon start—encorafenib plus cetuximab, using routine care rather than extra trial treatment.
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
Hear when a new BRAF V600E-mutant Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.